Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhenium-186-obisbemeda
- Development stage
- Phase 2
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intraventricular, Intrathecal
01
Overview
Rhenium-186-obisbemeda is a novel injectable radiotherapeutic agent developed for the treatment of central nervous system (CNS) cancers. It consists of the radioisotope rhenium-186 chelated with BMEDA and encapsulated within a nanoliposome. The drug is designed to deliver highly targeted radiation directly to tumor sites in the CNS while minimizing exposure to healthy tissue. Rhenium-186 emits both beta energy for therapeutic effect and gamma energy for real-time imaging of drug distribution and tumor targeting[1][8]. The agent is administered via direct intraventricular or intrathecal injection using an Ommaya reservoir, bypassing the blood-brain barrier and enabling precise delivery to tumors such as recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers[1][4]. In clinical trials, it has demonstrated significant tumor reduction with minimal toxicity compared to standard external beam radiation therapy[1][9].
- Brand names
- REYOBIQ
- Other names
- rhenium Re186 obisbemedaRhenium (186-Re) Obisbemeda186Re-Nanoliposome BMEDA
Beyond the preview
Go deeper on rhenium-186-obisbemeda.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhenium-186-obisbemeda.